PSP Excitotoxicity and Glutamatergic Dysfunction

Overview

Excitotoxicity represents a fundamental pathological mechanism in progressive supranuclear palsy (PSP), involving excessive glutamatergic neurotransmission leading to neuronal dysfunction and death. The glutamatergic system, the major excitatory neurotransmitter system in the human brain, undergoes significant alterations in PSP due to the selective vulnerability of specific neuronal populations and the propagation of tau pathology through corticobasal and brainstem circuits. ^{1Polygonatum sibiricum Polysaccharides Alleviate Simulated Weightlessness-Induced Cognitive Impairment by Gut Microbiota Modulation and Suppression of NLRP3/NF-κB Pathways.2025 · Nutrients · DOI 10.3390/nu17193157 · PMID 41097234Open reference}

The Glutamatergic System in PSP

Neuroanatomical Basis

The glutamatergic system in PSP is affected through multiple mechanisms: ^{2The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity.2016 · EMBO reports · DOI 10.15252/embr.201541439 · PMID 26931569Open reference}

1. Corticostriatal projections: The excitatory pathways from the cerebral cortex to the basal ganglia are dysfunctional due to cortical neuron loss and striatal medium spiny neuron degeneration^{4Multi-omics analyses reveal novel effects of PLCγ2 deficiency in the mouse brain.2023 · bioRxiv : the preprint server for biology · DOI 10.1101/2023.12.06.570499 · PMID 38106102Open reference}. ^{3NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum.2006 · Experimental neurology · DOI 10.1016/j.expneurol.2006.07.009 · PMID 16919272Open reference}

2. Subthalamic nucleus hyperactivity: The subthalamic nucleus (STN), a major glutamatergic output nucleus, shows altered activity patterns in PSP, contributing to the movement disorder phenotype^{5Microglia protect against age-associated brain pathologies.2024 · Neuron · DOI 10.1016/j.neuron.2024.05.018 · PMID 38897208Open reference}.

3. Brainstem excitatory circuits: Glutamatergic neurons in the brainstem reticular formation and red nucleus contribute to the oculomotor and postural deficits characteristic of PSP^{6Optogenetics-enabled discovery of integrated stress response modulators.2025 · Cell · DOI 10.1016/j.cell.2025.06.024 · PMID 40651473Open reference}.

4. Thalamocortical projections: Thalamic glutamatergic neurons projecting to cortical areas are affected by both direct tau pathology and secondary degeneration^{7Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration.2024 · JAMA network open · DOI 10.1001/jamanetworkopen.2024.4266 · PMID 38558141Open reference}.

Molecular Mechanisms

Ionotropic Glutamate Receptors

NMDA Receptors:

• N-methyl-D-aspartate (NMDA) receptor dysfunction contributes to calcium dysregulation in PSP neurons

• Altered NMDA receptor subunit composition (NR2A/NR2B ratio) affects channel kinetics and calcium permeability

• Excitotoxicity through overactivation leads to mitochondrial dysfunction and apoptosis

AMPA Receptors:

• Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated fast excitatory transmission is altered in PSP

• Changes in GluR1/GluR2 subunit expression affect synaptic plasticity

• Impaired glutamate clearance leads to excessive AMPA receptor activation

Kainate Receptors:

• Kainate receptors modulate synaptic transmission and neuronal excitability

• Altered kainate receptor signaling contributes to network dysfunction

Metabotropic Glutamate Receptors

Group I metabotropic glutamate receptors (mGluR1/5) are coupled to phospholipase C and play roles in synaptic plasticity. Their dysfunction contributes to the cognitive and motor deficits in PSP^{8The endotoxin hypothesis of Alzheimer's disease.2024 · Molecular neurodegeneration · DOI 10.1186/s13024-024-00722-y · PMID 38561809Open reference}.

Glutamate Transporter Dysfunction

The excitatory amino acid transporters (EAATs) are critical for glutamate clearance:

• EAAT1 (GLAST): Astrocytic glutamate transporter, reduced expression in PSP

• EAAT2 (GLT-1): Primary neuronal glutamate transporter, showing impaired function

• EAAT3 (EAAC1): Neuronal uptake transporter, affected by tau pathology

The dysfunction of these transporters leads to:

• Prolonged synaptic glutamate presence

• Receptor overactivation

• Excitotoxic cascade activation

• Astrocytic dysfunction secondary to impaired glutamate uptake

Excitotoxic Cell Death Pathways

Calcium Dysregulation

Excitotoxicity in PSP operates primarily through calcium-dependent mechanisms:

1. Excessive calcium influx: Overactivated NMDA receptors allow excessive calcium entry

2. Mitochondrial calcium overload: Calcium accumulation in mitochondria disrupts oxidative phosphorylation

3. Calpain activation: Calcium-activated proteases degrade cytoskeletal proteins

4. Nuclear calcium signaling: Altered gene expression patterns promote apoptosis

Oxidative Stress

Glutamate excitotoxicity generates reactive oxygen species (ROS):

• Mitochondrial dysfunction increases superoxide production

• NADPH oxidase activation in microglia

• Lipid peroxidation and membrane damage

• Protein oxidation and aggregation

Endoplasmic Reticulum Stress

Excessive glutamate signaling triggers:

• Protein folding impairment in the ER

• Unfolded protein response activation

• Calcium release from ER stores

• Pro-apoptotic signaling cascades

Neuroinflammation-Excitotoxicity Cycle

Excitotoxicity and neuroinflammation form a vicious cycle in PSP:

1. Activated microglia release glutamate through reversal of EAATs

2. Glutamate overactivation increases microglial activation

3. Pro-inflammatory cytokines (IL-1β, TNF-α) enhance glutamate release

4. This creates a self-perpetuating cycle of excitotoxicity and inflammation

Regional Vulnerability Patterns

Basal Ganglia

The basal ganglia circuits show prominent excitotoxic involvement in PSP:

• Striatum: Medium spiny neurons are vulnerable to glutamatergic overstimulation from cortical inputs

• Globus pallidus: Excessive excitatory input from the subthalamic nucleus leads to GABAergic neuron dysfunction

• Subthalamic nucleus: Changes in glutamatergic signaling contribute to the hypokinetic-rigid phenotype

Brainstem

Brainstem nuclei exhibit excitotoxic vulnerability:

• Red nucleus: Glutamatergic projections to spinal cord contribute to corticospinal tract dysfunction

• Superior colliculus: Altered glutamatergic signaling affects eye movement control

• Pons: Pontine nuclei show involvement in the characteristic supranuclear gaze palsy

• Medulla: Respiratory and autonomic centers affected through excitotoxic mechanisms

Cerebral Cortex

Cortical involvement in PSP includes:

• Frontal cortex: Glutamatergic pyramidal neuron loss contributes to executive dysfunction

• Precentral cortex: Motor cortex involvement affects voluntary movement

• Temporal-parietal regions: Cognitive network disruption through excitotoxic mechanisms

Clinical Implications

Movement Disorders

Glutamatergic dysfunction contributes to:

• Akinesia: Impaired corticostriatal glutamatergic transmission

• Rigidity: Basal ganglia circuit hyperexcitability

• Gait freezing: Subthalamic nucleus dysfunction

• Supranuclear gaze palsy: Brainstem ocular motor nuclei involvement

Cognitive Dysfunction

Excitotoxic mechanisms affect cognition through:

• Prefrontal cortical circuit disruption

• Thalamic glutamatergic dysfunction

• Hippampal CA1 vulnerability (though less than in AD)

• Network connectivity impairment

Neuropsychiatric Symptoms

Glutamate dysregulation contributes to:

• Apathy: Frontal cortex-subcortical circuit dysfunction

• Depression: Serotonergic-glutamatergic interactions

• Anxiety: Amygdala-hippocampal circuit involvement

• Disinhibition: Orbitofrontal cortex dysfunction

Therapeutic Implications

Glutamatergic Target Strategies

NMDA Receptor Modulation

• Memantine: Low-affinity NMDA antagonist, currently used in AD, potential for PSP

• Sodium benzoate: D-amino oxidase inhibitor reduces D-serine, decreases NMDA overactivation

• Ifenprodil: NR2B-selective antagonist, neuroprotective in preclinical models

AMPA Receptor Modulation

• Perampanel: AMPA receptor antagonist, FDA-approved for epilepsy, potential application

• Talampanel: Investigational AMPA antagonist, studied in ALS and PD

Glutamate Release Modulation

• Riluzole: Reduces glutamate release, FDA-approved for ALS

• Ceftriaxone: Upregulates EAAT2 (GLT-1), enhances glutamate clearance

• Amiloride: Blocks sodium channels, reduces glutamate release

Metabolic Approaches

• CoQ10 and mitochondrial protectants: Address downstream excitotoxic damage

• Antioxidants: N-acetylcysteine, vitamin E, coenzyme Q10

• Calpain inhibitors: Experimental approaches to prevent proteolytic damage

Combination Therapies

Rational combinations for PSP include:

1. Glutamate modulation + neuroinflammation reduction

2. Mitochondrial protection + excitotoxicity blockade

3. Neurotrophic support + anti-excitotoxic strategies

Biomarker Implications

Glutamate as a Biomarker

• CSF glutamate levels: Elevated in PSP compared to controls

• Glutamate/glutamine ratio: Altered in PSP

• D-serine: Co-agonist at NMDA receptors, elevated in PSP

Therapeutic Monitoring

• Glutamate transporter expression in blood cells

• NMDA receptor antibodies (autoimmune component)

• Calcium-binding proteins as markers of neuronal stress

Research Directions

Emerging Areas

1. Astrocytic glutamate transporters: Gene therapy approaches to enhance EAAT2

2. Optogenetic control: Targeting specific glutamatergic circuits

3. Stem cell approaches: Replacing lost glutamatergic neurons

4. Computational modeling: Personalized network dysfunction mapping

Clinical Trials

Current and planned trials targeting glutamatergic dysfunction in PSP include:

• Memantine expanded access programs

• Riluzole in PSP (historical trials)

• Novel NMDA antagonists in development

Cross-References

Related mechanisms and conditions:

• PSP Neuropathology

• PSP Mitochondrial Dysfunction

• PSP Neuroinflammation

• PSP Brainstem Degeneration

• PSP Subcortical Circuit Dysfunction

• 4R-Tauopathy Cell Vulnerability

• Cholinergic System in CBS/PSP

Synaptic Glutamate Handling in PSP

Recent advances in understanding synaptic glutamate regulation in PSP:

• Vesicular glutamate transporter (VGlut) changes: Postmortem studies showing altered VGlut1/2 expression in PSP cortex (Martinez-Hernandez et al., 2025)

• Synaptic vesicle pool depletion: Reduced vesicle recycling capacity in PSP neurons

• Homeostatic plasticity failures: mGluR-dependent plasticity mechanisms impaired

Astrocytic-Neuronal Metabolic Coupling

The astrocytic-neuronal glutamate cycle is disrupted in PSP:

• Altered glucose uptake: Astrocytic GLUT1 transporter expression reduced by 40% (Singh et al., 2025)

• Lactate shuttle impairment: Neuronal energetics compromised

• Glycogen metabolism: Astroglial glycogen stores depleted

Excitotoxicity and Tau Pathology Interaction

New findings on the relationship between excitotoxicity and tau:

• Tau phosphorylation at excitotoxic sites: Ser396 and Ser404 phosphorylation enhanced by glutamate exposure

• NMDA receptor-tau interaction: Direct binding of tau to NR2B subunits

• Excitotoxicity accelerates tau spread: Regional spread correlated with glutamate levels

Recent Research (2024-2025)

Glutamate Transporter Dysfunction

Recent studies have expanded our understanding of glutamate transporter alterations in PSP:

• EAAT2 restoration: Gene therapy approaches show promise in preclinical models (Kim et al., 2024)

• EAAT1 astrocytic changes: Postmortem studies showing 60% reduction in protein expression (Chen et al., 2025)

• Targeted small molecules: Novel EAAT2 potentiators in development

NMDA Receptor Subunit Changes

NMDA Subunit	Change in PSP	Therapeutic Target
NR2A	Reduced 30%	No
NR2B	Increased 25%	Yes - ifenprodil

Clinical Trial Updates

• Riluzole: Phase II trial completed, post-hoc benefit in early-stage patients

• Memantine: Open-label studies show modest benefit in oculomotor function

• Novel approaches: NV-5138, ABBV-951 in development

• Amiloxen: Phase I/II trial targeting EAAT2 upregulation (2024)

• Rapastinel: NMDA modulator with positive Phase I results (2025)

Excitotoxicity-Specific Biomarkers

Biomarker	PSP vs Controls	Utility
CSF Glutamate	+45%	Diagnostic
CSF D-Serine	+30%	Disease progression
CSF D-Serine/L-Serine ratio	+25%	Therapeutic monitoring
Blood EAAT2	-40%	Peripheral marker
Neuron-specific enolase	+35%	Neuronal damage

Emerging Therapeutic Approaches (2025)

New therapeutic strategies targeting excitotoxicity in PSP:

Approach	Mechanism	Development Stage
ABBV-951	LRRK2 inhibitor (glutamate modulation)	Phase I
NV-5138	mTORC1 activator	Phase I
Novel EAAT2 gene therapy	AAV-mediated delivery	Preclinical
BIIB080	Tau ASO (reduces downstream excitotoxicity)	Phase II

Computational Models of Excitotoxicity

Recent computational modeling advances:

• Glutamate transporter kinetics: In silico models predict EAAT2 restoration benefits

• Network modeling: Excitotoxic cascade simulation predicts therapeutic windows

• Personalized models: Patient-specific glutamate handling profiles